Unity Biotechnology’s (UBX) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital reissued their buy rating on shares of Unity Biotechnology (NASDAQ:UBX) in a report released on Monday morning,Benzinga reports. The brokerage currently has a $6.00 price objective on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Unity Biotechnology in a report on Monday.

Unity Biotechnology Stock Up 3.5 %

UBX opened at $1.78 on Monday. The firm has a 50-day simple moving average of $1.88 and a two-hundred day simple moving average of $1.51. Unity Biotechnology has a 52 week low of $0.94 and a 52 week high of $3.10. The company has a market capitalization of $29.99 million, a PE ratio of -1.36 and a beta of 1.02.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Unity Biotechnology stock. Bridgeway Capital Management LLC lifted its holdings in Unity Biotechnology, Inc. (NASDAQ:UBX) by 100.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 50,000 shares of the company’s stock after acquiring an additional 25,000 shares during the period. Bridgeway Capital Management LLC owned 0.30% of Unity Biotechnology worth $49,000 at the end of the most recent quarter. 29.49% of the stock is currently owned by institutional investors and hedge funds.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.